SEC ownership of Roivant Sciences Ltd.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001635088.

Comparable stake leader

FMR LLC

Disclosed value leader

FMR LLC

Comparable rows

50/50

Latest evidence

30 Sep 2026

Top shareholders Insider holders Latest transactions
Public ticker
ROIV on Nasdaq
Parsed ownership sources
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
FMR LLC
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
FMR LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Sep 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001635088
Issuer location
London

Ownership snapshot

Top shareholders of Roivant Sciences Ltd. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Sep 2026
13F 13D/G 3/4/5 Lead comparable stake: 10% 13D/G row: FMR LLC Showing 1-8 of 50 holder rows.

Quick read

FMR LLC leads the comparable SEC ownership view at 10%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FMR LLC's linked filing trail.
Comparable ownership Top 5
FMR LLC 10%
MORGAN STANLEY 5.7%
QVT Financial LP 4.3%
Vivek Ramaswamy 3.6%
VIKING GLOBAL INVESTORS LP 3.4%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FMR LLC
13F 13D/G
Company
13F 13D/G
10%
from 13D/G
$2,867,311,587
81,020,390 shares
 — 30 Jun 2026
MORGAN STANLEY
13F 13D/G
Company
13F 13D/G
5.7%
from 13D/G
$1,507,362,964
42,592,905 shares
 — 30 Jun 2026
QVT Financial LP
13F 13D/G 3/4/5
Company · Director by Deputization
13F 13D/G 3/4/5
4.3%
from 13D/G
$839,559,589
23,723,074 shares
 — 30 Jun 2026
Vivek Ramaswamy
3/4/5 13D/G
10%+ Owner · Ramaswamy Vivek
3/4/5 13D/G
3.6%
from 13D/G
$1,012,161,165
69,161,839 shares
mixed-class rows
 -$105,881,464 11 Dec 2025
VIKING GLOBAL INVESTORS LP
13D/G 3/4/5 13F
10%+ Owner · Company
13D/G 3/4/5 13F
3.4%
$356,989,793
23,594,831 shares
 -$161,027,803 30 Sep 2025
SB INVESTMENT ADVISERS (UK) LTD
13D/G
SB Investment Advisers (UK) Limited
13D/G
2.3%
$357,488,273
16,413,603 shares
 -$520,575,193 31 Dec 2025
Matthew Gline
3/4/5
CEO, Director
3/4/5
2.3%
$586,899,761
16,583,774 shares
 -$46,173,010 30 Sep 2026
BlackRock, Inc.
13F
Company
13F
6.8%
$1,707,075,250
48,236,091 shares
 — 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$904,340,251.

Buys
$0
Insiders: 0
Sells
$904,340,251
Insiders: 12
Net
-$904,340,251
Shares: -35,568,084
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 35,568,084
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 1,630,050 $0 $59,185,990 -$59,185,990
3-6 0 6,445,551 $0 $217,653,630 -$217,653,630
6-9 0 7,728,654 $0 $207,452,092 -$207,452,092
9-12 0 19,763,829 $0 $420,048,541 -$420,048,541

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 25 reporting-owner rows connected to Roivant Sciences Ltd.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
25
Largest Forms 3/4/5 holder
Dexcel Pharma Technologies Ltd.
Net 12M change
-$904,340,251
Latest report
30 Sep 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Dexcel Pharma Technologies Ltd. 10%+ Owner $1,064,491,735 Mixed 10 Nov 2022
Vivek Ramaswamy 10%+ Owner $1,012,161,165 -$105,881,464 -9.5% Mixed 11 Dec 2025
Daniel Allen Gold Director $800,253,968 -$147,382,307 -16% Mixed 16 Sep 2026
SVF Investments (UK) Ltd 10%+ Owner $755,877,753 Mixed 28 Sep 2023
Sumitomo Chemical Co., Ltd. 10%+ Owner $737,448,709 Mixed 22 Jun 2023
Mayukh Sukhatme President & CIO, Director $657,682,805 -$109,133,247 -14% Median 30 Sep 2026
Matthew Gline CEO, Director $586,899,761 -$46,173,010 -7.3% Median 30 Sep 2026
Keith S. Manchester Director $545,008,619 -$154,472,307 -22% Mixed 16 Sep 2026
QVT Financial LP Director by Deputization $482,953,776 -$147,382,307 -23% Filing P/S 26 Jun 2026
Frank Torti President and Vant Chair $477,619,653 -$82,039,460 -15% Median 30 Sep 2026
Eric Venker President & Immunovant CEO $181,428,314 -$97,091,062 -35% Mixed 30 Sep 2026
VIKING GLOBAL PERFORMANCE LLC 10%+ Owner $133,352,577 Mixed 22 Jun 2023
VIKING GLOBAL INVESTORS LP 10%+ Owner $133,352,577 Mixed 22 Jun 2023
Benjamin Zimmer President, Roivant Health $12,083,532 Mixed 01 Oct 2021
Richard Pulik Cfo $9,544,010 -$9,122,307 -49% Median 20 Sep 2026
Ilan Oren Director $4,377,035 Median 16 Sep 2026
James C. Momtazee Director $3,962,229 Median 16 Sep 2026
Jennifer Humes Chief Accounting Officer $3,766,168 -$384,073 -9.3% Median 20 Sep 2026
Rakhi Kumar Chief Accounting Officer $1,739,920 Mixed 20 Feb 2025
Meghan FitzGerald Director $1,456,723 -$3,271,652 -69% Median 16 Sep 2026

Recent insider transactions for Roivant Sciences Ltd.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Matthew Gline ROIV Common Shares Tax liability -0.46% -76,171 16,583,774 30 Sep 2026 Direct
Frank Torti ROIV Common Shares Tax liability 0.3% 40,309 13,495,893 30 Sep 2026 Direct
Mayukh Sukhatme ROIV Common Shares Tax liability -0.25% -46,879 18,583,860 30 Sep 2026 Direct
Eric Venker ROIV Common Shares Sale -11.1% $7,324,000 $36.62 -200,000 1,599,154 30 Sep 2026 Direct
Eric Venker ROIV Common Shares Options Exercise 12.5% 200,000 1,799,154 30 Sep 2026 Direct
Eric Venker ROIV Stock Option (Right to Buy) Options Exercise -5.2% -200,000 3,644,834 30 Sep 2026 Direct
Jennifer Humes ROIV Common Shares Tax liability -3.52% -3,880 106,419 20 Sep 2026 Direct
Richard Pulik ROIV Common Shares Tax liability -0.78% -2,129 269,681 20 Sep 2026 Direct
Keith S. Manchester ROIV Common Shares Award 0.29% 5,054 1,753,457 16 Sep 2026 Direct
Keith S. Manchester ROIV Stock Option (Right to Buy) Award 10,531 10,531 16 Sep 2026 Direct
Daniel Allen Gold ROIV Common Shares Award 0.06% 5,054 8,965,815 16 Sep 2026 Direct
Daniel Allen Gold ROIV Stock Option (Right to Buy) Award 10,531 10,531 16 Sep 2026 Direct
Ilan Oren ROIV Common Shares Award 4.26% 5,054 123,680 16 Sep 2026 Direct
Ilan Oren ROIV Stock Option (Right to Buy) Award 10,531 10,531 16 Sep 2026 Direct
James C. Momtazee ROIV Common Shares Award 4.73% 5,054 111,959 16 Sep 2026 Direct
James C. Momtazee ROIV Stock Option (Right to Buy) Award 10,531 10,531 16 Sep 2026 Direct
Meghan FitzGerald ROIV Common Shares Award 14% 5,054 41,162 16 Sep 2026 Direct
Meghan FitzGerald ROIV Stock Option (Right to Buy) Award 10,531 10,531 16 Sep 2026 Direct
Melissa B. Epperly ROIV Common Shares Award 51% 5,054 14,954 16 Sep 2026 Direct
Melissa B. Epperly ROIV Stock Option (Right to Buy) Award 10,531 10,531 16 Sep 2026 Direct
Melissa B. Epperly ROIV Common Shares Sale -33.3% $196,230 $39.74 -4,938 9,900 15 Sep 2026 Direct
Meghan FitzGerald ROIV Common Shares Sale -12.4% $203,152 $39.74 -5,112 36,108 15 Sep 2026 Direct
Daniel Allen Gold ROIV Common Shares Tax liability -0.06% -5,133 8,960,761 10 Sep 2026 Direct
Ilan Oren ROIV Common Shares Tax liability -1.97% -2,378 118,626 10 Sep 2026 Direct
Melissa B. Epperly ROIV Common Shares Tax liability -12.8% -2,179 14,838 10 Sep 2026 Direct
Meghan FitzGerald ROIV Common Shares Tax liability -4.06% -1,743 41,220 10 Sep 2026 Direct
James C. Momtazee ROIV Common Shares Tax liability -2.65% -2,905 106,905 10 Sep 2026 Direct
Meghan FitzGerald ROIV Common Shares Sale -31.8% $798,000 $39.90 -20,000 42,963 08 Sep 2026 Direct
Meghan FitzGerald ROIV Common Shares Options Exercise 46.6% 20,000 62,963 08 Sep 2026 Direct
Meghan FitzGerald ROIV Stock Option (Right to Buy) Options Exercise -51.8% -20,000 18,578 08 Sep 2026 Direct
Eric Venker ROIV Common Shares Sale -11.1% $7,153,393 $35.77 -200,000 1,599,154 28 Aug 2026 Direct
Eric Venker ROIV Common Shares Options Exercise 12.5% 200,000 1,799,154 28 Aug 2026 Direct
Eric Venker ROIV Stock Option (Right to Buy) Options Exercise -4.94% -200,000 3,844,834 28 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Sale -0.77% $5,280,699 $36.48 -144,756 18,630,739 21 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Options Exercise 0.78% 144,756 18,775,495 21 Aug 2026 Direct
Mayukh Sukhatme ROIV Stock Option (Right to Buy) Options Exercise -1.08% -144,756 13,224,363 21 Aug 2026 Direct
Richard Pulik ROIV Common Shares Tax liability -2.07% -5,749 271,810 20 Aug 2026 Direct
Eric Venker ROIV Common Shares Tax liability -0.86% -13,909 1,599,154 20 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Sale -0.09% $653,459 $37.30 -17,519 18,630,739 20 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Options Exercise 0.09% 17,519 18,648,258 20 Aug 2026 Direct
Mayukh Sukhatme ROIV Stock Option (Right to Buy) Options Exercise -0.13% -17,519 13,369,119 20 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Sale -0.92% $6,426,656 $37.17 -172,899 18,630,739 19 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Options Exercise 0.93% 172,899 18,803,638 19 Aug 2026 Direct
Mayukh Sukhatme ROIV Stock Option (Right to Buy) Options Exercise -1.28% -172,899 13,386,638 19 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Sale -0.73% $5,029,470 $36.73 -136,942 18,630,739 18 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Options Exercise 0.74% 136,942 18,735,880 18 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Options Exercise -1% -136,942 13,559,537 18 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Sale -1.51% $10,320,629 $36.25 -284,707 18,630,739 17 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Options Exercise 1.53% 284,707 18,915,446 17 Aug 2026 Direct
Mayukh Sukhatme ROIV Common Shares Options Exercise -2.04% -284,707 13,696,479 17 Aug 2026 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .